دورية أكاديمية
أعرض في EDS

Role of fecal calprotectin as a hypoxic intestinal damage biomarker in COVID-19 patients.

التفاصيل البيبلوغرافية
العنوان: Role of fecal calprotectin as a hypoxic intestinal damage biomarker in COVID-19 patients.
المؤلفون: Adriana DN; Department of Internal Medicine, Faculty of Medicine, Soetomo Teaching Hospital, Universitas Airlangga, Dr, Surabaya, 60286, Indonesia., Sugihartono T; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia. titongsppd@gmail.com., Nusi IA; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Setiawan PB; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Purbayu H; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Maimunah U; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Kholili U; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Widodo B; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Thamrin H; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Vidyani A; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia., Maulahela H; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia., Yamaoka Y; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia. yyamaoka@oita-u.ac.jp.; Helicobacter Pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, 60115, Indonesia. yyamaoka@oita-u.ac.jp.; Department of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan. yyamaoka@oita-u.ac.jp.; Department of Medicine, Gastroenterology and Hepatology Section, Baylor College of Medicine, Houston, TX, USA. yyamaoka@oita-u.ac.jp., Miftahussurur M; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia.; Helicobacter Pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, 60115, Indonesia.
المصدر: Gut pathogens [Gut Pathog] 2022 Aug 09; Vol. 14 (1), pp. 34. Date of Electronic Publication: 2022 Aug 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101474263 Publication Model: Electronic Cited Medium: Print ISSN: 1757-4749 (Print) Linking ISSN: 17574749 NLM ISO Abbreviation: Gut Pathog Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central
مستخلص: Background: Gastrointestinal manifestations of coronavirus disease 2019 (COVID-19) appear to be substantial. Fecal calprotectin is a promising biomarker in COVID-19 associated gastrointestinal inflammation; however, its role in the severity of COVID-19 remains limited. We conducted a study to analyze the relationship between the severity of COVID-19 and hypoxic intestinal damage.
Methods: We assessed the severity of 44 hospitalized COVID-19 pneumonia patients based on the PaO2/FiO2 (P/F) ratio. Inflammatory markers were measured from blood samples, and fecal calprotectin was obtained from stool samples.
Results: Median levels of fecal calprotectin in COVID-19 patients involved in this study (n = 44) were found to be markedly elevated along with the severity of hypoxemia, as seen in the non-acute respiratory distress syndrome (ARDS) group 21.4 µg/g (5.2-120.9), mild ARDS 54.30 µg/g (5.2-1393.7), moderate ARDS 169.6 µg/g (43.4-640.5), and severe ARDS 451.6 µg/g (364.5-538.6). We also found significant differences in fecal calprotectin levels based on the severity of ARDS (P < 0.001), and although the patients were divided into ARDS and non-ARDS groups (P < 0.001). Furthermore, we found a strong negative correlation between the P/F ratio and fecal calprotectin levels (r = - 0.697, P < 0.001).
Conclusion: Our findings support the potential role of fecal calprotectin as a biomarker of intestinal inflammation in COVID-19 as a consequence of hypoxic intestinal damage and as suggested by the reduced P/F ratio.
(© 2022. The Author(s).)
References: Nat Clin Pract Gastroenterol Hepatol. 2005 May;2(5):216-22. (PMID: 16265204)
Chest. 2007 Aug;132(2):410-7. (PMID: 17573487)
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):534-535. (PMID: 32304638)
World J Gastroenterol. 2021 Jun 14;27(22):3130-3137. (PMID: 34168414)
Gastroenterology. 2020 Jul;159(1):81-95. (PMID: 32251668)
Dig Liver Dis. 2020 Nov;52(11):1231-1233. (PMID: 33060042)
Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):387-404. (PMID: 15123077)
Am J Physiol Gastrointest Liver Physiol. 2020 Aug 1;319(2):G245-G252. (PMID: 32639848)
Int J Infect Dis. 2020 Jul;96:467-474. (PMID: 32425643)
Gastroenterology. 2021 Jun;160(7):2623-2625. (PMID: 32425230)
Sci Rep. 2021 Jun 25;11(1):13308. (PMID: 34172783)
Gut. 2020 Aug;69(8):1543-1544. (PMID: 32312790)
Lancet Respir Med. 2020 Apr;8(4):420-422. (PMID: 32085846)
Inflamm Bowel Dis. 2020 Aug 20;26(9):1306-1314. (PMID: 32720978)
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):269-283. (PMID: 33589829)
J Biol Chem. 2020 Jul 24;295(30):10493-10505. (PMID: 32503843)
Gastroenterol Hepatol (N Y). 2017 Jan;13(1):53-56. (PMID: 28420947)
N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
Annu Rev Pathol. 2016 May 23;11:77-100. (PMID: 27193451)
Cell Rep. 2020 Jul 21;32(3):107915. (PMID: 32649864)
Dig Dis Sci. 2020 Jul;65(7):1932-1939. (PMID: 32447742)
Gut. 2020 Jun;69(6):1002-1009. (PMID: 32213556)
Front Mol Biosci. 2018 Nov 29;5:89. (PMID: 30555831)
Expert Rev Gastroenterol Hepatol. 2014 Feb;8(2):197-210. (PMID: 24345070)
Am J Gastroenterol. 2020 Jul;115(7):1003-1006. (PMID: 32618648)
Dig Liver Dis. 2021 Mar;53(3):295-297. (PMID: 33132062)
J Clin Med. 2021 Feb 15;10(4):. (PMID: 33672040)
JAMA. 2012 Jun 20;307(23):2526-33. (PMID: 22797452)
Am J Gastroenterol. 2020 May;115(5):766-773. (PMID: 32287140)
Mayo Clin Proc. 2020 Aug;95(8):1632-1648. (PMID: 32753138)
J Intensive Care. 2020 Jul 10;8:49. (PMID: 32665858)
Sci Rep. 2021 Apr 1;11(1):7334. (PMID: 33795768)
J Investig Med. 2020 Dec;68(8):1397-1401. (PMID: 32928903)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Int J Environ Res Public Health. 2021 Nov 02;18(21):. (PMID: 34770046)
Sci Rep. 2021 Nov 9;11(1):22001. (PMID: 34753964)
Healthcare (Basel). 2021 Jul 29;9(8):. (PMID: 34442092)
Trop Med Infect Dis. 2020 Sep 16;5(3):. (PMID: 32947803)
Nat Med. 2020 May;26(5):681-687. (PMID: 32327758)
J Clin Med. 2020 Nov 11;9(11):. (PMID: 33187280)
فهرسة مساهمة: Keywords: COVID-19; Fecal calprotectin; Infectious disease; P/F ratio
تواريخ الأحداث: Date Created: 20220809 Latest Revision: 20220813
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9360717
DOI: 10.1186/s13099-022-00507-y
PMID: 35945626
قاعدة البيانات: MEDLINE
الوصف
تدمد:1757-4749
DOI:10.1186/s13099-022-00507-y